Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management
January 19, 2024
06:00 PM - 08:00 PM PST
James J. Harding, MD
Kanwal Raghav, MD
Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know
Biree Andemariam, MD
Caroline Freiermuth, MD
Keeping Pace in Hematologic Malignancies: 2023Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Harry Paul Erba, MD, PhD
Courtney DiNardo, MD
Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
Joseph Mikhael, MD
Monique Hartley-Brown, MD
Brandon Blue, MD
In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer
John L. Marshall, MD
Individualizing Frontline Treatment
Alex Herrera, MD
Alison J. Moskowitz, MD
Patient Selection for ADCs in First-Line DLBCL
John P. Leonard, MD
Sarah Rutherford, MD
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Kami Maddocks, MD
Matthew J. Matasar, MD
Bispecific Antibodies in FL
Application of Data from the ECHELON-1 Trial
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
NCCN Guideline Updates in DLBCL
Antibody-Drug Conjugates in FL
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
Late-Stage Bispecifics and ADCs in DLBCL
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Jason J. Luke, MD, FACP
Tara C. Mitchell, MD
Loading...
Stay current with the best on medical education
We’re glad to see you’re enjoying Prova Education…but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.